PEPG PepGen Inc. Insider Trading

Oxford Science Enterprises acquired 200,000 shares of PEPG at $3.20; company unprofitable with $-23.1M net income.

Oxford Science Enterprises purchased 200,000 shares of PepGen Inc. at $3.20 on 2025-09-30, increasing its stake from 4,755,388 shares to 4,955,388 shares (+4.2%). The transaction occurred when the stock was trading significantly below its 52-week high of $9.76 (currently -51.7% from peak), following a sharp 30-day rally of +306.0%. However, the underlying company remains unprofitable with a net income of $-23.1M over the most recent full fiscal year, creating tension between the recent price momentum and the loss-making fundamentals. The timing coincides with substantial short-term volatility, and investors should evaluate whether this purchase reflects a substantive view on the turnaround prospect or simply positions the major shareholder within a volatile trading pattern in an unprofitable biotech company.

RA Capital Management bought 9,375,000 shares of PEPG at $3.20 for $30.0M, doubling director holdings to 18,554,273 shares

RA Capital Management purchased 9,375,000 shares (9.38M shares) at $3.20 on 2025-09-26, representing a $30,000,000.00 ($30.0M) investment that doubled its post-transaction holdings from 9,179,273 to 18,554,273 shares (+102.1%). The purchase occurred near the 52-week low range while the stock has surged +298.3% over the past 30 days, suggesting the director's timing captured a significant downside point before a recent rally. However, PepGen remains operationally challenged with full-year net income of $-23,087,000.00 ($-23.1M), making the company unprofitable, and the stock still trades -52.7% below its 52-week high despite the recent momentum. This substantial capital commitment by an insider director merits scrutiny of both the underlying business recovery trajectory and whether the recent price recovery is durable.

PEPG EVP Paul Streck buys 8,375 shares at $1.24 amid 92.2% decline from 52-week high; company posted $-30.2M net loss.

Paul Streck, EVP and Head of R&D, purchased 8,375 shares at $1.24, increasing his holdings by 43.1%. The transaction occurred as the stock trades at $1.44, down 92.2% from its 52-week high of $18.55 and fallen 36.8% over the past 90 days. PepGen reported a full-year net loss of $-30.2M, indicating material operational challenges. The combination of a junior insider (R&D leader) accumulating shares in a depressed price environment while the company remains unprofitable warrants investor attention to execution and capital allocation risk.

PEPG CEO buys 10.0K shares at $1.36; stock -91.3% from 52-week high, company unprofitable ($-21.4M net income)

McArthur James G purchased 10,000 shares at $1.36, increasing his holdings by 9.6% to 113.9K shares. The timing of this buy merits attention: his prior 2023-11-30 buy at this ticker yielded 90-day returns of +254.9%, and across all his open-market trades, he has a 100.00% 90-day win rate with an average 90-day return of +254.9%. However, PEPG itself is showing distress—the stock trades at $1.62 (current), down 91.3% from its 52-week high of $18.55, and the company reported a full-year net loss of $-21.4M against a $53.0M market cap. McArthur's purchase occurs just 9 days after his April 8 buy, suggesting persistent accumulation despite deteriorating fundamentals and severe price depreciation. The gap between his historical cross-ticker success and the current weakness at PEPG suggests this accumulation warrants scrutiny of whether his track record translates to this distressed situation.

PepG CEO James McArthur buys 41,500 shares at $1.15 amid 93.9% decline from 52-week high; stock down 67.2% in 90 days while CEO boosts holdings 66.5%.

McArthur James G, President and CEO of PepGen Inc., purchased 41,500 shares at $1.15 on 2025-04-08, increasing his holdings from 62,413 shares to 103,913 shares—a 66.5% increase in personal stake. The purchase occurs at an extreme market moment: the stock is trading at $1.13, down 93.9% from its 52-week high of $18.55 and down 67.2% over the prior 90 days. Notably, McArthur's prior open-market buy at this ticker on 2023-11-30 was well-timed, with the stock returning +254.9% over the subsequent 90 days. Against this backdrop of severe recent price deterioration, the CEO's substantial insider purchase—while his cross-ticker track record shows strong average returns—warrants scrutiny given the company's unprofitable status (net income of $-21,384,000 in the most recent fiscal year) and the stock's dramatic recent weakness.